Streetbeat News

Regulatory

MSFT

Scarlett Johansson declined an offer from OpenAI to be the voice of their ChatGPT assistant, but the company seemingly used a voice modeled after hers anyway. This led to legal action from Johansson, prompting OpenAI to take down the voice. The incident highlights broader issues with AI training practices and the need for regulations to protect creators.

Portfolio Pulse from Aaron Bry

May 21, 2024 | 8:14 pm

CDRO

Codere Online Luxembourg has received a late-filing notice from Nasdaq, indicating a delay in submitting its financial report.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 8:10 pm

INFN

Infinera has received a delinquency notification from Nasdaq, indicating that the company is not in compliance with Nasdaq's listing requirements.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 8:09 pm

DDC

DDC Enterprise has received a noncompliance notice from NYSE American. The company's Class A Ordinary Shares will remain listed on the NYSE American as it works to regain compliance with listing standards, provided it meets other continued listing requirements.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 8:02 pm

NUWE

Nuwellis has been granted U.S. Patent #11986584 for its 'Extracorporeal Blood Filtering Machine and Methods'. This patent could enhance the company's competitive edge in the medical device market.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 7:59 pm

MSFT

Elon Musk criticized OpenAI for allegedly mimicking Scarlett Johansson's voice in its GPT-4o model. Johansson has taken legal action against OpenAI, which is backed by Microsoft (NASDAQ:MSFT). OpenAI denies the allegations, claiming the voice belongs to a different actress. This incident raises ethical and intellectual property concerns in AI development.

Portfolio Pulse from Rounak Jain

May 21, 2024 | 7:19 pm

CBSTF

GTBIF

Ohio's medical marijuana companies, including Green Thumb Industries and the Cannabist Company, are preparing to enter the recreational cannabis market following regulatory approvals. Dual-use applications will be available by June 7, and the DEA's reclassification of marijuana to a Schedule III drug will reduce tax burdens for these businesses.

Portfolio Pulse from Maureen Meehan

May 21, 2024 | 7:08 pm

GLD

SLV

British economist Philip Pilkington warns that the next U.S. recession could lead to a significant decline in American living standards due to private foreign investors dumping U.S. Treasuries. The article also mentions the iShares Silver Trust (SLV) and Ethereum (ETH) making new highs.

Portfolio Pulse from David Pinsen

May 21, 2024 | 6:53 pm

WORX

SCWorx Corp. has received a notice from Nasdaq for failing to timely file its Form 10-Q for the period ended March 31, 2024, and remains delinquent in filing its Form 10-K for the year ended December 31, 2023. This failure violates Nasdaq Listing Rule 5250(c)(1).

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 6:40 pm

BIIB

LRMR

Larimar Therapeutics announced that the FDA has lifted the partial clinical hold on its investigational drug nomlabofusp (CTI-1601) for Friedreich’s Ataxia. The decision follows positive data from a Phase 2 study. Nomlabofusp showed promising results in increasing frataxin levels and was well-tolerated. The ongoing OLE study will further evaluate its safety and efficacy. William Blair reiterates an Outperform rating on Larimar. The stock rose 10.66% following the news.

Portfolio Pulse from Vandana Singh

May 21, 2024 | 6:39 pm